PRNewsWire
09 Jun 2026, 02:22 UTC · 22w ago
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
Impact · against what's priced in
IDEAYA Biosciences' $300 million equity offering is a dilutive event that puts immediate downward pressure on the stock price, despite the resulting increase in cash runway for R&D. The news is not material for the underwriters J.P. Morgan and UBS.
- IDYA−0.20
No priced-in read yet





